C4 Therapeutics announces 2023 strategic priorities

C4 Therapeutics announced 2023 strategic priorities to advance its portfolio of targeted protein degradation medicines. CFT7455: CFT7455 is an oral degrader of IKZF1/3 for the treatment of multiple myeloma and non-Hodgkin’s lymphomas. Recent Achievements: Progression of the ongoing Phase 1/2 clinical trial with the opening of Arm B2, evaluating CFT7455 in combination with dexamethasone for the treatment of MM.2023 Objectives: Continue dose escalation in Arms B1, B2 and C of the Phase 1/2 trial, evaluating CFT7455 as a single agent in MM, in combination with dexamethasone in MM, and as a single agent in NHL, respectively. Present Phase 1 dose escalation data from the ongoing Phase 1/2 trial of CFT7455 in MM in the second half of 2023. CFT8634: CFT8634 is an oral degrader of BRD9 for the treatment of synovial sarcoma and SMARCB1-null solid tumors. Recent Achievements: Pharmacokinetic and pharmacodynamic data from the initial escalation cohorts of the ongoing CFT8634 Phase 1/2 trial demonstrate dose proportional exposure, strong oral bioavailability and deep BRD9 degradation. 2023 Objectives: Continue dose escalation of the CFT8634 Phase 1/2 trial in synovial sarcoma and SMARCB1-null solid tumors. Present Phase 1 dose escalation data from the ongoing CFT8634 Phase 1/2 trial in the second half of 2023. CFT1946: CFT1946 is an oral degrader targeting BRAF-V600 mutations for the treatment of solid tumors including non-small cell lung cancer, colorectal cancer and melanoma.Recent Achievements: Initiated the Phase 1/2 trial of CFT1946 for the treatment of BRAF-V600 mutant cancers including NSCLC, colorectal cancer and melanoma. 2023 Objectives: Advance the dose escalation portion of the CFT1946 Phase 1/2 trial in BRAF-V600 mutant solid tumors. Present new preclinical data on the discovery and characterization of CFT1946 as a potent, selective, and orally bioavailable degrader for the treatment of BRAF-V600-driven cancers at a medical meeting in the first half of 2023. CFT8919: CFT8919 is a potent and selective oral degrader of EGFR L858R for the treatment of NSCLC. Recent Achievements: Completed investigational new drug enabling activities for CFT8919. 2023 Objectives: Submit an IND application for CFT8919 for the treatment of NSCLC in the first half of 2023.